Clinical Trials Sponsored by Ology Bioservices

Total 38 results

Ology Bioservices

Completed

Reverse Genetic H9N2 Influenza Vaccine Study in Adults

Influenza

United States
Ology Bioservices

Completed

Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Whole Virion, Vero Cell Derived)

Influenza

Germany, Austria
Ology Bioservices

Completed

Comparison of the Safety and Immune Response of Three Different Lots of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2004/2005

Influenza

Austria, Germany
Ology Bioservices

Completed

Comparison of the Safety and Immune Response of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2003/2004

Influenza

Poland
Ology Bioservices

Completed

A/H1N1 Immunogenicity and Safety in Adults

Influenza | Pandemic Influenza

Austria, Germany
Ology Bioservices

Completed

Safety and Immunogenicity Study of a Booster Vaccination With a Non-Adjuvanted H5N1 Influenza Vaccine (Follow Up to Study 810501)

Influenza

Austria
Ology Bioservices

Completed

Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in Adults

Influenza | Avian Influenza

Austria, Finland
Ology Bioservices

Completed

Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)

Influenza

Singapore, Hong Kong
Ology Bioservices

Completed

Safety and Immunogenicity Study of a Ross River Virus (RRV) Vaccine

Ross River Virus Disease (RRVD)

Netherlands, Austria, Belgium
Ology Bioservices

Completed

Safety and Immunogenicity Study of a H5N1 Influenza Vaccine (Vero Cell-Derived, Whole Virus) in Healthy Infants, Children and Adolescents

Influenza, Avian

Australia, Finland, Singapore, Spain
Ology Bioservices

Completed

Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)

Influenza

Austria, Germany, Poland
Ology Bioservices

Completed

Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)

Influenza

United States
Ology Bioservices

Completed

Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults

Phase 1 Safety Study of GelVac Nasal Powder H5N1 Influenza Vaccine

United States
Ology Bioservices

Completed

Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection

Influenza

United States
Ology Bioservices

Completed

Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older

Influenza

United States
Ology Bioservices

Completed

Observational Study to Assess Safety of H1N1 Pandemic Influenza Vaccine

Influenza | Pandemic Influenza

Austria
Ology Bioservices

Completed

Adult Safety Study of 2009/2010 Seasonal Influenza Vaccine

Influenza

Austria, Belgium
Ology Bioservices

Completed

Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801

Prophylaxis of Ross River Virus Infection

Australia
Ology Bioservices

Completed

Phase 3 Study of a H5N1 Vaccine in Adults, Elderly and Specified Risk Groups

Influenza

Austria, Belgium, Finland, Germany, Latvia, Lithuania, Netherlands
Ology Bioservices

Completed

Pilot Study of PRX-03140 to Assess Safety for Use in Adult Subjects With Post Traumatic Stress Disorder

Post Traumatic Stress Disorder

United States
Ology Bioservices

Completed

Yearly Strain Variation Study, 2010/2011

Influenza | Seasonal Influenza

Austria
Ology Bioservices

Completed

Phase 1 Study of a H5N1 Influenza Vaccine (Reverse Genetic Reassortant)

Influenza | Pandemic Influenza

United States
Ology Bioservices

Completed

H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and Older

Influenza

Japan
Ology Bioservices

Completed

Ross River Virus (RRV) Vaccine Study

Prophylaxis of Ross River Virus Infection

Australia
Ology Bioservices

Completed

Phase 3 Immunogenicity and Safety Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)

Influenza

Germany, Austria
Ology Bioservices

Completed

Safety and Immunogenicity Study of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)

Influenza

Singapore, Austria
Ology Bioservices

Completed

Yearly Strain Variation Study, 2009/2010

Influenza | Seasonal Influenza

Austria
Ology Bioservices

Completed

A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents

Influenza | Pandemic Influenza

Austria, Germany
Ology Bioservices
Enabling Biotechnologies (EB)

Not yet recruiting

Study to Evaluate the Safety and Efficacy of a Monoclonal Antibody Cocktail for the Prevention of COVID-19

COVID-19

Mali, Mexico
Ology Bioservices
Baxter Innovations GmbH

Completed

H5N1 Vaccine Study in Japanese Adults

H5N1 Influenza

Japan
Ology Bioservices
Enabling Biotechnologies (EB)

Completed

Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19

SARS-CoV-2

United States
Ology Bioservices
Baxter Innovations GmbH

Completed

Japanese Pediatric H5N1 Vaccine Study

Influenza

Japan
Ology Bioservices
United States Department of Defense

Active, not recruiting

Repeat Dose of G03-52-01 in Adult Subjects

Healthy | Botulinum Toxin

United States
Ology Bioservices
United States Department of Defense

Active, not recruiting

Study to Evaluate Safety and PK of a Single IM Dose of G03-52-01 vs Placebo in Adult Subjects

Healthy

United States
Ology Bioservices
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Study to Evaluate Safety and PK of NTM-1634 vs Placebo Administered Intravenously in Healthy Adults

Healthy

United States
Ology Bioservices
Pharm-Olam, LLC; Chemical, Biological, Radiological, and Nuclear Medical

Withdrawn

Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT) (COMBAAT)

Mild to Moderate COVID-19
Rafa Laboratories
Ology Bioservices; Joint Project Management Office for Chemical, Biological...

Completed

Study of Midazolam in Healthy Adults

Status Epilepticus

United States
Phoenix Children's Hospital
Jazz Pharmaceuticals; Fisher Bioservices

No longer available

Erwinase Master Treatment Protocol (EMTP)

Acute Lymphoid Leukemia | Leukemia, Acute Lymphoblastic

3

Subscribe